News headlines about Innoviva (NASDAQ:INVA) have been trending somewhat positive on Monday, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Innoviva earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 45.143631640073 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted Accern’s analysis:
- Analyzing Innoviva (INVA) & Its Competitors (americanbankingnews.com)
- GlaxoSmithKline : Glaxo (GSK) Files for U.S. Label Expansion of COPD Inhaler (4-traders.com)
- Innoviva, Inc. (INVA) Receives Average Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Innoviva, Inc. (NASDAQ: INVA) – In Play Stock Characteristics – Alpha Beta Stock (alphabetastock.com)
- Jagged Peak Energy Inc., (NYSE: JAG), Innoviva, Inc., (NASDAQ: INVA), Citigroup Inc., (NYSE: C), Conagra Brands … – Stocks In The News (press release) (tradingnewsnow.com)
Innoviva (INVA) opened at $13.26 on Monday. Innoviva has a 1-year low of $10.07 and a 1-year high of $14.87. The company has a market capitalization of $1,432.28, a P/E ratio of 15.24 and a beta of 2.51. The company has a current ratio of 6.71, a quick ratio of 6.71 and a debt-to-equity ratio of -2.59.
Innoviva (NASDAQ:INVA) last issued its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.21 EPS for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.13). Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The business had revenue of $48.64 million for the quarter, compared to analyst estimates of $57.18 million. During the same quarter last year, the firm earned $0.13 earnings per share. The firm’s quarterly revenue was up 46.0% compared to the same quarter last year. equities research analysts anticipate that Innoviva will post 1.08 EPS for the current year.
Several equities research analysts recently weighed in on INVA shares. ValuEngine lowered Innoviva from a “buy” rating to a “hold” rating in a report on Friday, September 1st. Stifel Nicolaus restated a “neutral” rating on shares of Innoviva in a report on Friday, September 15th. Zacks Investment Research upgraded Innoviva from a “hold” rating to a “buy” rating and set a $16.00 target price for the company in a report on Wednesday, October 25th. Robert W. Baird restated a “hold” rating and issued a $13.00 target price on shares of Innoviva in a report on Tuesday, October 24th. Finally, Morgan Stanley restated an “underweight” rating and issued a $8.00 target price (up from $7.00) on shares of Innoviva in a report on Friday, October 6th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and two have assigned a buy rating to the stock. Innoviva presently has a consensus rating of “Hold” and an average price target of $13.50.
In other news, VP George B. Abercrombie sold 5,215 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.26, for a total transaction of $69,150.90. Following the completion of the transaction, the vice president now directly owns 263,866 shares in the company, valued at $3,498,863.16. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Eric Desparbes sold 15,285 shares of the company’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $13.28, for a total value of $202,984.80. Following the transaction, the chief financial officer now owns 337,027 shares of the company’s stock, valued at $4,475,718.56. The disclosure for this sale can be found here. 1.60% of the stock is owned by insiders.
Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).
Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with MarketBeat.com's FREE daily email newsletter.